• Something wrong with this record ?

A rat model of early sepsis: relationships between gentamicin pharmacokinetics and systemic and renal effects of bacterial lipopolysaccharide combined with interleukin-2

S. Studena, J. Martinkova, D. Slizova, O. Krs, M. Senkerik, D. Springer, J. Chládek,

. 2012 ; 35 (10) : 1703-10.

Language English Country Japan

Document type Journal Article, Research Support, Non-U.S. Gov't

A rat model of early sepsis induced by lipopolysaccharide (LPS) combined with interleukin-2 (IL-2) was developed. The primary aim was to assess the pharmacokinetics of gentamicin and sepsis-induced pathophysiological changes. Moreover, the effects on the glomerular filtration rate and tubular function were studied in septic and control rats. First, an intravenous (i.v.) bolus of LPSIL-2 (1 mg/kg-Pseudomonas aeruginosa, 15 µg/kg IL-2) or saline (controls, C) was administred. The Wistar rats were treated 30 min after LPSIL-2 with gentamicin as a 3 mg/kg i.v. bolus followed 10 min later by an i.v. 170-min infusion (GE, 0.09 mg/kg·min(-1)). The monitoring of vital functions, biochemistry and GE concentrations was performed. Creatinine clearance was 2-3 times lower and fractional urea excretion was 3-4 times less in septic rats as compared to controls(p<0.05), although urine flow was comparable. Capillary leakage caused a 55% elevation in the volume of distribution (V(c)) in the LPSIL+GE group vs. C+GE (p<0.05). The renal CL(ge) was less (2.2±0.59 vs. 3.8±0.53 mL/min·kg(-1), p<0.05), while the total CL(ge) was comparable (5.9±1.5 vs. 6.7±1.1 mL/min·kg(-1); p=0.30). In the LPSIL+GE group relative to C+GE, the half-life (t(1/2)) was 79% higher (p<0.05) and GE concentrations detected at the end of the study in the plasma and kidney were elevated 2.5-fold (p=0.09) and 2.2-fold (p<0.05), respectively. The model reproduced several consequences of early sepsis like in patients such as capillary leak, a decreased glomerular filtration rate (GFR) and the changes in pharmacokinetics of GE (increased values of V(c) and t(1/2) and a drop in renal CL(ge) proportional to that of CL(cr)). Nonrenal routes which, for the most part, compensate the reduced renal CL(ge) in septic rats deserve further study.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13012407
003      
CZ-PrNML
005      
20130410094012.0
007      
ta
008      
130404s2012 ja f 000 0|eng||
009      
AR
024    7_
$a 10.1248/bpb.b12-00205 $2 doi
035    __
$a (PubMed)23037160
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ja
100    1_
$a Studena, Sarka $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University in Prague, Czech Republic.
245    12
$a A rat model of early sepsis: relationships between gentamicin pharmacokinetics and systemic and renal effects of bacterial lipopolysaccharide combined with interleukin-2 / $c S. Studena, J. Martinkova, D. Slizova, O. Krs, M. Senkerik, D. Springer, J. Chládek,
520    9_
$a A rat model of early sepsis induced by lipopolysaccharide (LPS) combined with interleukin-2 (IL-2) was developed. The primary aim was to assess the pharmacokinetics of gentamicin and sepsis-induced pathophysiological changes. Moreover, the effects on the glomerular filtration rate and tubular function were studied in septic and control rats. First, an intravenous (i.v.) bolus of LPSIL-2 (1 mg/kg-Pseudomonas aeruginosa, 15 µg/kg IL-2) or saline (controls, C) was administred. The Wistar rats were treated 30 min after LPSIL-2 with gentamicin as a 3 mg/kg i.v. bolus followed 10 min later by an i.v. 170-min infusion (GE, 0.09 mg/kg·min(-1)). The monitoring of vital functions, biochemistry and GE concentrations was performed. Creatinine clearance was 2-3 times lower and fractional urea excretion was 3-4 times less in septic rats as compared to controls(p<0.05), although urine flow was comparable. Capillary leakage caused a 55% elevation in the volume of distribution (V(c)) in the LPSIL+GE group vs. C+GE (p<0.05). The renal CL(ge) was less (2.2±0.59 vs. 3.8±0.53 mL/min·kg(-1), p<0.05), while the total CL(ge) was comparable (5.9±1.5 vs. 6.7±1.1 mL/min·kg(-1); p=0.30). In the LPSIL+GE group relative to C+GE, the half-life (t(1/2)) was 79% higher (p<0.05) and GE concentrations detected at the end of the study in the plasma and kidney were elevated 2.5-fold (p=0.09) and 2.2-fold (p<0.05), respectively. The model reproduced several consequences of early sepsis like in patients such as capillary leak, a decreased glomerular filtration rate (GFR) and the changes in pharmacokinetics of GE (increased values of V(c) and t(1/2) and a drop in renal CL(ge) proportional to that of CL(cr)). Nonrenal routes which, for the most part, compensate the reduced renal CL(ge) in septic rats deserve further study.
650    _2
$a zvířata $7 D000818
650    _2
$a antibakteriální látky $x krev $x farmakokinetika $x moč $7 D000900
650    _2
$a kapilární permeabilita $x účinky léků $7 D002199
650    12
$a modely nemocí na zvířatech $7 D004195
650    _2
$a gentamiciny $x krev $x farmakokinetika $x moč $7 D005839
650    _2
$a hodnoty glomerulární filtrace $x účinky léků $7 D005919
650    _2
$a interleukin-2 $x aplikace a dávkování $7 D007376
650    _2
$a ledviny $x účinky léků $x metabolismus $x patofyziologie $7 D007668
650    _2
$a lipopolysacharidy $x aplikace a dávkování $7 D008070
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a sepse $x metabolismus $x patofyziologie $7 D018805
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Martinkova, Jirina $u -
700    1_
$a Slizova, Dasa $u -
700    1_
$a Krs, Otakar $u -
700    1_
$a Senkerik, Marian $u -
700    1_
$a Springer, Drahomira $u -
700    1_
$a Chládek, Jaroslav $u -
773    0_
$w MED00000729 $t Biological & pharmaceutical bulletin $x 1347-5215 $g Roč. 35, č. 10 (2012), s. 1703-10
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23037160 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130404 $b ABA008
991    __
$a 20130410094241 $b ABA008
999    __
$a ok $b bmc $g 975605 $s 810688
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 35 $c 10 $d 1703-10 $i 1347-5215 $m Biological & pharmaceutical bulletin $n Biol Pharm Bull $x MED00000729
LZP    __
$a Pubmed-20130404

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...